新型肿瘤标志物用于原发性肝癌诊断的临床研究

目的探讨AFP-L3、GPC3、AFU三者联合检测模式对诊疗原发性肝癌(PHC)的效果。方法选择肝癌患者100例(PHC组),肝硬化患者50例(肝硬化组),正常对照者50例(对照组),用酶联免疫法分别测出AFP-L3、GPC3和AFU的浓度。然后分别按照检测项目进行统计分析。结果 (1)PHC组的AFP-L3阳性率明显高于肝硬化组和对照组(P<0.01);肝硬化组的阳性率与对照组差异无统计学意义(P>0.05)。(2)PHC组的GPC3阳性率明显高于肝硬化组和对照组(P<0.01);肝硬化组的阳性率与对照组差异无统计学意义(P>0.05)。(3)PHC组的AFU阳性率明显高于肝硬化组和对照组(P<0.01);肝硬化组阳性率与正常对照组差异有统计学意义(P<0.01)。(4)AFP-L3、GPC3、AFU三者联合检测时,高于任何单项检测的敏感度、特异度和准确度。结论 AFP-L3、GPC3、AFU三者联合检测可以提高PHC诊断的敏感度、特异度和准确度。

A study on the clinical significance of new tumor markers in the diagnosis of primary hepatocellular carcinoma

Objective To investigate the clinical significance of combination detection of AFP-L3, GPC3 and AFU in the diagnosis and treatment of primary hepatocellular carcinoma（PHC）. Methods The concentrations of AFP-L3 ,GPC3, AFU were detected by enzyme-linked immunosorbent assay（ELISA） in 100 patients with PHC （PHC group）,50 patients with cirrhosis（ cirrhosis group）and 50 healthy subjects（ control group）, then the results were statistically analyzed. Results The positive rate of AFP-L3 in PHC group was significantly higher than that in cirrhosis group or control group （ P 〈 0.01）, however, there was no significant difference between cirrhosis group and control group （ P 〉 0. 05 ）. The positive rate of GPC3 in PHC group was significantly higher than that in cirrhosis group or control group（ P 〈 0.01 ） ,however,there was no significant difference between cirrhosis group and control group （ P 〉 0.05 ）. The positive rate of AFU in PHC group was significantly higher than that in cirrhosis group or control group（ P 〈 0.01 ） , however, there was no significant difference between cirrhosis group and control group （ P 〉 O. 05 ）. The sensitivity, specificity and accuracy of combination detection of AFP-L3, GPC3 ,AFU were higher than those of any simple item detection. Conclusion The combination detection of AFP-L3, GPC3, AFU can enhance the sensitivity, specificity and accuracy in the diagnosis of PHC.